Investigational drugs for pruritus

Expert Opinion on Investigational Drugs

Volumn 22, Issue 9, 2013, Pages 1167-1179

  Benecke, Heike ^a   Lotts, Tobias ^b   Ständer, Sonja ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chronic pruritus; Neurokinin 1 receptor; Opioid receptors; Therapy of CP

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; A 940894; A 987306; ANTIPRURITIC AGENT; APREPITANT; CAPSAICIN; CZC 13788; GASTRIN RELATED PEPTIDE RECEPTOR; HISTAMINE H1 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; IMMUBALANCE; INCB 38579; INTERLEUKIN 31; INTERLEUKIN 31 RECEPTOR; INTERLEUKIN RECEPTOR; NALFURAFINE; NALOXONE; NERVE GROWTH FACTOR; PF 2988403; PIMECROLIMUS; PROTEINASE ACTIVATED RECEPTOR 2; RECEPTOR; SEMAPHORIN 3A; TACROLIMUS; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNCLASSIFIED DRUG;

CHRONIC PRURITUS; DRUG TARGETING; HUMAN; NEUROBIOLOGY; NEURODERMATITIS; NONHUMAN; PRURITUS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHRONIC DISEASE; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR TARGETED THERAPY; PRURITUS; QUALITY OF LIFE; SKIN;

EID: 84882272329     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.813932     Document Type: Review

References (169)

1. Ständer S, Ständer H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007;156(5):1020-6
2. Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol 2013;168(6):1273-80
3. Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010;221(3):229-35
4. Kremer AE, Martens JJWW, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139(3):1008-18, 1018.e1
5. Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 2013;123(4):1513-30
6. Matsuda H, Watanabe N, Geba GP, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997;9(3):461-6
7. Tanaka A, Matsuda H. Evaluation of itch by using NC/NgaTnd mice: a model of human atopic dermatitis. J Biomed Biotechnol 2011;2011:790436
8. Tanaka A, Amagai Y, Oida K, Matsuda H. Recent findings in mouse models for human atopic dermatitis. Exp Anim 2012;61(2):77-84
9. Sugimoto Y, Umakoshi K, Nojiri N, Kamei C. Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice. Eur J Pharmacol 1998;351(1):1-5
10. Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65(4):516-28
11. Hossen MA, Sugimoto Y, Kayasuga R, Kamei C. Involvement of histamine H3 receptors in scratching behaviour in mast cell-deficient mice. Br J Dermatol 2003;149(1):17-22
12. Sugimoto Y, Iba Y, Nakamura Y, et al. Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin Exp Allergy 2004;34(3):456-9
13. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb/c mice. Br J Pharmacol 2004;142(2):374-80
14. Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007;119(1):176-83
15. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Investig Dermatol 2009;130(4):1023-33
16. Rossbach K, Wendorff S, Sander K, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009;18(1):57-63
17. Bäumer W, Wendorff S, Gutzmer R, et al. Histamine H4 receptors modulate dendritic cell migration through skin-immunomodulatory role of histamine. Allergy 2008;63(10):1387-94
18. Gutzmer R, Mommert S, Gschwandtner M, et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol 2009;123(3):619-25
19. Dijkstra D, Leurs R, Chazot P, et al. Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. J Allergy Clin Immunol 2007;120(2):300-7
20. Dijkstra D, Stark H, Chazot PL, et al. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J Invest Dermatol 2008;128(7):1696-703
21. Gschwandtner M, Rossbach K, Dijkstra D, et al. Murine and human Langerhans cells express a functional histamine H4 receptor: modulation of cell migration and function. Allergy 2010;65(7):840-9
22. Gschwandtner M, Mommert S, Kother B, et al. The histamine H4 receptor is highly expressed on plasmacytoid dendritic cells in psoriasis and histamine regulates their cytokine production and migration. J Invest Dermatol 2011;131(8):1668-76
23. Mommert S, Gschwandtner M, Koether B, et al. Human memory Th17 cells express a functional histamine H4 receptor. Am J Pathol 2012;180(1):177-85
24. Lazewska D, Kiec-Kononowicz K. Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed) 2012;4:967-87
25. Shin N, Covington M, Bian D, et al. INCB38579, a novel and potent histamine H(4) receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur J Pharmacol 2012;675(1-3):47-56
26. Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004;309(1):404-13
27. Kiss R, Keseru GM. Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat 2012;22(3):205-21
28. Ohsawa Y, Hirasawa N. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012;67(8):1014-22
29. Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther 2010;23(6):590-6
30. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5(7):752-60
31. Diveu C, Lak-Hal AL, Froger J, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw 2004;15(4):291-302
32. Takaoka A, Arai I, Sugimoto M, et al. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005;516(2):180-1
33. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117(2):411-17
34. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013;24(1):48-53.e11-2
35. Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006;118(4):930-7
36. Takaoka A, Arai I, Sugimoto M, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006;15(3):161-7
37. Ezzat MHM, Hasan ZE, Shaheen KYA. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011;25(3):334-9
38. Raap U, Weissmantel S, Gehring M, et al. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol 2012;23(3):285-8
39. Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31- antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009;18(1):35-43
40. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin-where do we stand? Exp Dermatol 2009;18(5):424-30
41. Phan NQ, Lotts T, Antal A, et al. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venerol 2012;92(5):555-60
42. Kuraishi Y, Yageta Y, Konno M, et al. Intracisternal, but not intrathecal, injection of naloxone inhibits cutaneous itch-related response in mice. Biol Pharm Bull 2008;31(11):2143-5
43. Inan S, Dun NJ, Cowan A. Nalfurafine prevents 5'-guanidinonaltrindole-and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice. Neuroscience 2009;163(1):23-33
44. Liu X, Liu Z, Sun Y, et al. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 2011;147(2):447-58
45. Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface. QJM 2003;96(1):7-26
46. Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs 2006;18(3):227-33
47. Ko MCH, Song MS, Edwards T, et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004;310(1):169-76
48. Pan ZZ. mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 1998;19(3):94-8
49. Carstens E, Akiyama T, Carstens MI. Differential itch-and pain-related behavioral responses and ?-opoid modulation in mice. Acta Derm Venerol 2010;90(6):575-81
50. Umeuchi H, Togashi Y, Honda T, et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003;477(1):29-35
51. Kamei J, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001;418(1-2):141-5
52. Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002;435(2-3):259-64
53. Wakasa Y, Fujiwara A, Umeuchi H, et al. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 2004;75(24):2947-57
54. Umeuchi H, Kawashima Y, Aoki CA, et al. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride. Eur J Pharmacol 2005;518(2-3):133-9
55. Wang Y, Tang K, Inan S, et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005;312(1):220-30
56. Inan S, Cowan A. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 2006;85(1):39-43
57. Nakao K, Ikeda K, Kurokawa T, et al. Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis. Nihon Shinkei Seishin Yakurigaku Zasshi 2008;28(2):75-83
58. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006;54(3):527-31
59. Lee H, Naughton NN, Woods JH, Ko M. Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 2007;107(3):478-85
60. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol 2010;63(4):680-8
61. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16(12):3742-7
62. Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25(4):1251-7
63. Inui S. Nalfurafine hydrochloride for the treatment of pruritus. Expert Opin Pharmacother 2012;13(10):1507-13
64. Sun Y, Chen Z. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448(7154):700-3
65. Sun Y, Zhao Z, Meng X, et al. Cellular basis of itch sensation. Science 2009;325(5947):1531-4
66. Yao R, Li T, Xu J, et al. Design, synthesis and anti-itch activity evaluation of aromatic amino acid derivatives as gastrin-releasing peptide receptor antagonists. Med Chem 2012;8(5):865-73
67. Liu T, Berta T, Xu Z, et al. TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice. J Clin Invest 2012;122(6):2195-207
68. Andoh T, Kuwazono T, Lee J, Kuraishi Y. Gastrin-releasing peptide induces itch-related responses through mast cell degranulation in mice. Peptides 2011;32(10):2098-103
69. Rukwied R, Lischetzki G, McGlone F, et al. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000;142(6):1114-20
70. Tanaka A, Matsuda H. Expression of nerve growth factor in itchy skins of atopic NC/NgaTnd mice. J Vet Med Sci 2005;67(9):915-19
71. Groneberg DA, Serowka F, Peckenschneider N, et al. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol 2005;161(1-2):87-92
72. Albers KM, Wright DE, Davis BM. Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of the peripheral nervous system. J Neurosci 1994;14(3 Pt 2):1422-32
73. Takano N, Sakurai T, Ohashi Y, Kurachi M. Effects of high-affinity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model. Br J Dermatol 2007;156(2):241-6
74. Negi O, Tominaga M, Tengara S, et al. Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis. J Dermatol Sci 2012;66(1):37-43
75. Matsuda A, Tanaka A, Pan W, et al. Supplementation of the fermented soy product ImmuBalance effectively reduces itching behavior of atopic NC/Tnd mice. J Dermatol Sci 2012;67(2):130-9
76. Ikezawa Z, Komori J, Ikezawa Y, et al. A role of Staphyococcus aureus, interleukin-18, nerve growth factor and semaphorin 3A, an axon guidance molecule, in pathogenesis and treatment of atopic dermatitis. Allergy Asthma Immunol Res 2010;2(4):235-46
77. Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol 2011;165(2):277-84
78. Kou K, Nakamura F, Aihara M, et al. Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin. Acta Derm Venereol 2012;92(5):521-8
79. Wallengren J, Ekman R, Sundler F. Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Derm Venereol 1987;67(3):185-92
80. Pincelli C, Fantini F, Massimi P, et al. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990;122(6):745-50
81. Chan J, Smoller BR, Raychauduri SP, et al. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997;289(11):611-16
82. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 1998;286(3):1140-5
83. Brain SD. New feelings about the role of sensory nerves in inflammation. Nat Med 2000;6(2):134-5
84. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6(2):151-8
85. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995;275(3):229-33
86. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci 2006;7(7):535-47
87. Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B (4) in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117(6):1621-6
88. Kanai H, Nagashima A, Hirakata E, et al. The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients. Life Sci 1995;57(3):207-13
89. Andoh T, Kuraishi Y. Inhibitory effects of azelastine on substance P-induced itch-associated response in mice. Eur J Pharmacol 2002;436(3):235-9
90. Bozic CR, Lu B, Hopken UE, et al. Neurogenic amplification of immune complex inflammation. Science 1996;273(5282):1722-5
91. Costa SKP, Starr A, Hyslop S, et al. How important are NK1 receptors for influencing microvascular inflammation and itch in the skin? Studies using Phoneutria nigriventer venom. Vascul Pharmacol 2006;45(4):209-14
92. Cuellar JM, Jinks SL, Simons CT, Carstens E. Deletion of the preprotachykinin A gene in mice does not reduce scratching behavior elicited by intradermal serotonin. Neurosci Lett 2003;339(1):72-6
93. Lee JH, Cho SH. Korean red ginseng extract ameliorates skin lesions in NC/Nga mice: an atopic dermatitis model. J Ethnopharmacol 2011;133(2):810-17
94. Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 2006;7(8):975-92
95. Chang S, Han S, Jung H, Choi J. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007;156(6):1272-7
96. Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010;5(6):e10968
97. Akiyama T, Tominaga M, Davoodi A, et al. Roles for substance P and gastrin-releasing peptide as neurotransmitters released by primary afferent pruriceptors. J Neurophysiol 2013;109(3):742-8
98. Benecke H, Wäring J, Lotts T, Ständer S. Transient receptor potential channels and pruritus. In: Szallasi A, B?́ró T, editors. TRP channels in drug discovery: volume II. Springer, Human Press; New York, Heidelberg: 2012. p. 255-78
99. Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 2009;106(27):11330-5
100. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002;11(1):12-24
101. B?́ró T, Toth BI, Marincsak R, et al. TRP channels as novel players in the pathogenesis and therapy of itch. Biochim Biophys Acta 2007;1772(8):1004-21
102. Shim W, Tak M, Lee M, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007;27(9):2331-7
103. Kim S, Park GH, Kim D, et al. Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons. Proc Natl Acad Sci USA 2011;108(8):3371-6
104. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389(6653):816-24
105. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000;288(5464):306-13
106. B?́ró T, Maurer M, Modarres S, et al. Characterization of functional vanilloid receptors expressed by mast cells. Blood 1998;91(4):1332-40
107. Denda M, Fuziwara S, Inoue K, et al. Immunoreactivity of VR1 on epidermal keratinocyte of human skin. Biochem Biophys Res Commun 2001;285(5):1250-2
108. Inoue K, Koizumi S, Fuziwara S, et al. Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun 2002;291(1):124-9
109. Ständer S, Moormann C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004;13(3):129-39
110. Basu S, Srivastava P. Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells. Proc Natl Acad Sci USA 2005;102(14):5120-5
111. Bodó E, B?́ró T, Telek A, et al. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol 2005;166(4):985-98
112. Mishra SK, Hoon MA. The cells and circuitry for itch responses in mice. Science 2013;340(6135):968-71
113. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21(3):531-43
114. Szallasi A, Blumberg PM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 1989;30(2):515-20
115. Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006;126(8):1705-18
116. Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995;32(2 Pt 1):287-9
117. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001;44(3):471-8
118. Jessell TM, Iversen LL, Cuello AC. Capsaicin-induced depletion of substance P from primary sensory neurones. Brain Res 1978;152(1):183-8
119. Dallos A, Kiss M, Polyanka H, et al. Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. Neuropeptides 2006;40(4):251-63
120. Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011;11(5):420-7
121. Belghiti M, Estevez-Herrera J, Gimenez-Garzo C, et al. Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease. J Biol Chem 2013;288(14):9675-85
122. Inagaki N, Shiraishi N, Igeta K, et al. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone. Eur J Pharmacol 2006;546(1-3):189-96
123. Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992;26(1):91-4
124. Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993;29(3):438-42
125. Green BG, Shaffer GS. The sensory response to capsaicin during repeated topical exposures: differential effects on sensations of itching and pungency. Pain 1993;53(3):323-34
126. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999;81(1-2):135-45
127. Liang J, Ji Q, Ji W. Role of transient receptor potential ankyrin subfamily member 1 in pruritus induced by endothelin-1. Neurosci Lett 2011;492(3):175-8
128. Kim D, Kim H, Sung K, et al. 12(S)-HPETE induces itch-associated scratchings in mice. Eur J Pharmacol 2007;554(1):30-3
129. Kim D, Kim H, Kim H, et al. Involvement of serotonin receptors 5-HT1 and 5-HT2 in 12(S)-HPETEinduced scratching in mice. Eur J Pharmacol 2008;579(1-3):390-4
130. Kim AY, Tang Z, Liu Q, et al. Pirt, a phosphoinositide-binding protein, functions as a regulatory subunit of TRPV1. Cell 2008;133(3):475-85
131. Patel KN, Liu Q, Meeker S, et al. Pirt, a TRPV1 modulator, is required for histamine-dependent and-independent itch. PLoS One 2011;6(5):e20559
132. Ständer S, Metze D. Treatment of pruritic skin diseases with topical capsaicin. In: Yosipovitch G, Greaves MW, Fleischer AB, McGlone F, editors. Itch: basic mechanisms and therapy. Marcel Dekker; New York, Basel: 2004. p. 287-304
133. Gooding SMD, Canter PH, Coelho HF, et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010;49(8):858-65
134. Yun J, Seo JA, Jang W, et al. Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models. J Invest Dermatol 2011;131(7):1576-9
135. Yun J, Seo JA, Jeong YS, et al. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery. J Dermatol Sci 2011;62(1):8-15
136. Lim K, Park Y. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res 2012;35(3):393-6
137. Sekine R, Satoh T, Takaoka A, et al. Anti pruritic effects of topical crotamiton, capsaicin, and a corticosteroid on pruritogen-induced scratching behavior. Exp Dermatol 2012;21(3):201-4
138. Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 2008;28(5):1064-75
139. Xiao B, Patapoutian A. Scratching the surface: a role of pain-sensing TRPA1 in itch. Nat Neurosci 2011;14(5):540-2
140. Bandell M, Story GM, Hwang SW, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004;41(6):849-57
141. Jordt S, Bautista DM, Chuang H, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004;427(6971):260-5
142. Bautista DM, Movahed P, Hinman A, et al. Pungent products from garlic activate the sensory ion channel TRPA1. Proc Natl Acad Sci USA 2005;102(34):12248-52
143. Bautista DM, Jordt S, Nikai T, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006;124(6):1269-82
144. Macpherson LJ, Hwang SW, Miyamoto T, et al. More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci 2006;32(4):335-43
145. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003;112(6):819-29
146. Dai Y, Wang S, Tominaga M, et al. Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. J Clin Invest 2007;117(7):1979-87
147. Tsujii K, Andoh T, Lee J, Kuraishi Y. Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and-independent pathways in mice. J Pharmacol Sci 2008;108(3):385-8
148. Liu T, Ji R. Oxidative stress induces itch via activation of transient receptor potential subtype ankyrin 1 in mice. Neurosci Bull 2012;28(2):145-54
149. Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptormediated itch. Nat Neurosci 2011;14(5):595-602
150. Costa R, Marotta DM, Manjavachi MN, et al. Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. Br J Pharmacol 2008;154(5):1094-103
151. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23(15):6176-80
152. Shimada SG, Shimada KA, Collins JG. Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. Eur J Pharmacol 2006;530(3):281-3
153. Liu Q, Weng H, Patel KN, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal 2011;4(181):ra45
154. Shim W, Oh U. Histamine-induced itch and its relationship with pain. Mol Pain 2008;4:29
155. Han JH, Choi H, Kim SJ. Topical TRPM8 agonist (icilin) relieved vulva pruritus originating from lichen sclerosus et atrophicus. Acta Derm Venereol 2012;92(5):561-2
156. B?́ró T, Ko MC, Bromm B, et al. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 2005;14(3):225-40
157. Bharate SS, Bharate SB. Modulation of thermoreceptor TRPM8 by cooling compounds. ACS Chem Neurosci 2012;3(4):248-67
158. McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002;416(6876):52-8
159. Peier AM, Moqrich A, Hergarden AC, et al. A TRP channel that senses cold stimuli and menthol. Cell 2002;108(5):705-15
160. Cho Y, Jang Y, Yang YD, et al. TRPM8 mediates cold and menthol allergies associated with mast cell activation. Cell Calcium 2010;48(4):202-8
161. Medic N, Desai A, Komarow H, et al. Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria. Cell Calcium 2011;50(5):473-80
162. Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol 2012;92(5):563-81
163. Ständer S, Darsow U, Mettang T, et al. S2k guideline-chronic pruritus. J Dtsch Dermatol Ges 2012;10(Suppl 4):S1-27
164. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363(4):397-8
165. Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012;13(10):1020-4
166. Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009;361(14):1415-16
167. Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 2011;164(3):665-7
168. Torres T, Fernandes I, Selores M, et al. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 2012;66(1):e14-15
169. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010;18(9):1229-30